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Abstract
Background: Urothelial carcinoma of the urinary bladder (UCB) is the 4th most common cancer type in men in
developed countries, and tumor recurrence or progression occurs in more than half of the patients. Previous
studies report contradictory trends in incidence and survival over the past decades. This article describes the trends
of UCB incidence and survival from 1981 to 2014, including both invasive and non-invasive UCB using data from
the Cancer Registry of Norway.
Methods: In Norway, 33,761 patients were diagnosed with UCB between 1981 and 2014. Incidence and 5-year
relative survival were calculated, stratified by sex, morphology, stage, age and diagnostic period. Age-period-cohort
models were used to distinguish period- and cohort effects. Temporal trends were summarized by calculating the
average absolute annual change in incidence and relative survival allowing for breaks in this trend by incorporating
a joinpoint analysis. Excess mortality rate ratios (EMRR) quantify the relative risks by using a proportional excess
hazard model.
Results: The incidence of UCB in men increased from 18.5 (1981-85) to 21.1 (1991-95) per 100 000 person-years
and was rather stable thereafter (1996–2014). The incidence rates of UCB were lower in women increasing linearly
from 4.7 to 6.2 over the past 34 years (p = 5.9 · 10-7). These trends could be explained by an increase of the
incidence rates of non-invasive tumors. Furthermore, the observed pattern seemed to represent a birth cohort
effect. Five-year relative survival increased annually with 0.004 in men (p = 1.3 · 10-6) and 0.003 in women (p = 4.5 ·
10-6). There is a significant increase over the past 34 years in survival of UCB in both genders for local tumors but
not for advanced stages.
Conclusions: Increasing and stable incidence trends mirror little improvement in primary and secondary prevention
of UCB for more than three decades. Survival proportions increased only marginally. Thus, any changes in treatment
and follow-up care did not lead to notable improvement with respect to survival of the patients. High estimates of
preventable cases together with large recurrence rates of this particular cancer type, demand more research on
prevention guidelines, diagnostic tools and treatment for UCB.
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Background
Despite large global differences in the incidence of
urothelial carcinoma of the urinary bladder (UCB), this
cancer type remains the second most common genito-
urinary malignancy after prostate cancer in men world-
wide. Globally, about 330 000 new UCB cases were
diagnosed and 123 000 UCB patients died from the dis-
ease in 2012. UCB is most frequent in Europe, Northern
America, Western Asia and Northern Africa and least
common in Eastern, Western and Middle Africa, Central
America and the non-western regions of Asia [1].
Within Europe, UCB is the fourth most common cancer
type in men with an age-standardized incidence rate
(world) of 17.7 per 100 000 person-years [1]. The corre-
sponding rate in Norway is 20.8 per 100 000 person-
years based on the diagnosis period from 2009 to 2013
[2]. UCB incidence in women is much lower with 3.5
cases per 100 000 person-years in Europe and 6.4 in
Norway. International variation in UCB incidence have
recently been described in detail [3], also including
trends over time.
Several risk factors have been identified for UCB, to-
bacco smoking being the most predominant one. The
population attributable risk for ever smoking has lately
been estimated to be approximately 50 % in both men
and women in the US [4] and nearly 40 % in the UK [5].
Men are more likely to get UCB with a male to female
ratio of 3.2 in Norway [2]. UCB is also related to occupa-
tional exposure to certain chemicals like aromatic
amines, chlorinated hydrocarbons and polycyclic aro-
matic hydrocarbons [6, 7]. Patients previously irradiated
for pelvic and abdominal malignancies are also at in-
creased risk, as is also shown for intake of certain drugs
used in previous cancer treatment [8] as well as diabetes
medication [9]. UCB rarely occurs before the age of 40,
and has a median age of diagnosis at 75 in the UK [10].
In Norway, 95 % of all UCB cases are of the transi-
tional cell type, and about 60 % are primarily diagnosed
without invasion into subepithelial connective tissue
(tumor stage T1) or muscle (T2-4). These non-invasive
tumors (papillary: Ta, Carcinoma in situ: Tis) and dys-
plasia are characterized by its high recurrence rates after
transurethral resection of an initial tumor. Non-invasive
papillary (Ta) tumors form the largest group and ac-
count for half of all diagnosed urothelial carcinomas.
The majority of these tumors will recur, but the risk of
progression to invasive UCB is low (4–7 %) for low-
grade Ta tumors and approximately 12–23 % for high-
grade Ta tumors [11, 12]. Carcinoma in situ seems to be
more likely to progress than non-invasive papillary
tumors, especially if concurrent with papillary tumors
[12, 13]. The high recurrence rates and the low but
imminent progression risk leads to a tight follow-up of
the patients with frequent visits and resource demanding
treatment as well. This makes UCB one of the most ex-
pensive cancers to treat on a per-patient basis [14] in
addition to being bothersome for the patients.
Incidence and survival trends for UCB in different
countries based on cancer registry data have been de-
scribed previously [15–17]. However, inclusion and ex-
clusion criteria differ with respect to diagnose groups
and periods as well as classification and registration
practices. Furthermore, to our knowledge, none of the
articles addressing UCB trends used a nationwide regis-
try. We will describe the trends of UCB incidence and
survival over time in Norway for all patients diagnosed
with urothelial carcinoma of the urinary bladder be-
tween 1981 and 2014, including both invasive and non-
invasive UCB (including dysplasia) using data from the
Cancer Registry of Norway.
Methods
Material
The Cancer Registry of Norway has since 1953, compul-
sory by law, registered virtually all new cancer diagnoses
in Norway. The registry receives information from three
independent sources (clinicians, pathology laboratories,
and from the Cause of Death Registry), which ensures
completeness and high quality data [18]. Patients are
identified through the unique national personal identifi-
cation number assigned to all newborns and residents in
Norway since 1960. The present study comprises all new
cases of histologically verified invasive and non-invasive
urothelial carcinoma of the urinary bladder in the
Norwegian population diagnosed between 1981 and
2014. UCB cases were selected based on morphological
codes for the transitional cell type as presented in
Table 1. UCB patients diagnosed before 1981 were ex-
cluded due to registration changes in the seventies
mainly for non-invasive tumors. Thus, in total, 33,761
UCB patients were included in this study (Table 1).
Participants were followed until death, migration or
end of follow up on the 31st of March 2016. The
total follow-up time was 230 783 person-years with a
median follow-up time of 15.0 years. Out of all
33,761 UCB patients included in this study, 5 228 in-
dividuals died from UCB according to the cause of
death certificate.
Information on morphology, stage, grade, sex, age at
diagnosis and date of diagnosis were retrieved from the
Cancer Registry of Norway. Morphology, stage and grade
were defined based on the most severe diagnosis within a
5-month window including the first of the month when
the first UCB diagnosis was received. We define five
morphology groups based on the available tumor categor-
ies and grade information: Non-invasive papillary carcin-
oma low- and high-grade (Ta), non-invasive flat
carcinoma (Tis), dysplasia (low-grade flat carcinoma) and
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invasive carcinoma (T1-T4). Grade information is based
on WHO 1973 [19] and grouped into low (LG, WHO
grade 1 and 2)- and high-grade (HG, WHO grade 3) (see
Table 1). Stage is categorizsed as localized (non-invasive/
invasive cancer without any metastases), regional ad-
vanced (any infiltration into surrounding areas or regional
metastases) and distant advanced (distant metastases) tu-
mors. For the presentation of the results, age at diagnosis
was divided into four age groups (≤49, 50–64, 65–79,
≥80). The year of diagnosis is grouped into 5-years inter-
vals (diagnostic periods): 1981–1985, 1986–1990, …,
2006–2010 and 2011–2014.
Statistics
Incidence rates (per 100 000 person-years) were calcu-
lated based on the number of individuals getting their
first UCB diagnosis and the number of individuals living
in Norway for a certain sex, diagnostic time-period and
age group. Age-specific incidence rates are presented for
each of the four age-groups stratified for sex. Direct age-
standardized incidence rates were calculated applying
the World Standard Population [20] according to sex as
well as age group, morphology group and stage across
all diagnostic periods. Temporal trends of the incidence
rates were best represented by a linear model, where the
estimated regression coefficient β^I represents the average
absolute annual incidence change. In order to
summarize the observed trend over the last 34 years,
this parameter has been provided together with the
standard error and p-values for the test of an incidence
change over time. We also implemented a joinpoint ana-
lysis [21] to uncover trends, which change over time. In
order to interpret trends in age-specific incidence rates
over time, we also apply an extension of the age-period-
cohort model [22] to separate diagnosis period and birth
cohort effects. An APC model incorporating restricted
cubic splines, implemented in Stata was used [23, 24].
The APC model was applied for male patients with an
Table 1 Patient inclusion criteria
Morphology code Description Morphology group Number of individuals Percentage
8130 Papillary, mild dysplasia, non-invasive (WHO-grade I) Non-inv pap carcinoma LG 6752 20.0 %
8131 Papillary, moderate dysplasia, non-invasive (WHO-grade II) Non-inv pap carcinoma LG 7644 22.6 %
8136 Papillary, not otherwise specified (NOS), non-invasive Non-inv pap carcinoma LG 238 0.7 %
8132 Papillary, non-invasive, high-grade (WHO-grade III) Non-inv pap carcinoma HG 2400 7.1 %
8120 Non-papillary, mild dysplasia, non-invasive (WHO-grade I) Dysplasia 303 0.9 %
8121 Non-papillary, moderate dysplasia, non-invasive (WHO-grade II) Dysplasia 589 1.7 %
8126 Non-papillary, NOS, non-invasive Dysplasia 441 1.3 %
8122 Non-papillary, non-invasive, high-grade (WHO-grade III) Carcinoma in situ 1198 3.5 %
8123 Non-papillary, NOS, invasive Inv carcinoma 319 0.9 %
8124 Non-papillary, mild dysplasia, invasive (WHO-grade I) Inv carcinoma 28 0.1 %
8125 Non-papillary,moderate dysplasia, invasive (WHO-grade II) Inv carcinoma 758 2.2 %
8127 Non-papillary, invasive, high-grade (WHO-grade III) Inv carcinoma 3471 10.3 %
8133 Papillary, NOS, invasive Inv carcinoma 169 0.5 %
8134 Papillary, mild dysplasia, invasive (WHO-grade I) Inv carcinoma 237 0.7 %
8135 Papillary, moderate dysplasia, invasive (WHO-grade II) Inv carcinoma 2205 6.5 %
8137 Papillary, invasive, high-grade (WHO-grade III) Inv carcinoma 3304 9.8 %
80103a Carcinoma in situ, NOS Inv carcinoma 185 0.5 %
80203a Carcinoma, undifferentiated, invasive, NOS Inv carcinoma 91 0.3 %
812031a Highly differentiated, invasive, G1, low-grade Inv carcinoma 84 0.2 %
812032a Moderately differentiated, invasive, G2, low-grade Inv carcinoma 193 0.6 %
812033a Poorly differentiated, invasive, G3, high-grade Inv carcinoma 2180 6.5 %
812034a Undifferentiated, invasive, G4, high-grade Inv carcinoma 27 0.1 %
812039a NOS, invasive Inv carcinoma 945 2.8 %
Total number of individuals 33761
Morphology codes (MOTNAC: Manual of Tumor Nomenclature and Coding from 1951 from the American Cancer Society), description, morphology groups and
corresponding number and percentage of individuals included in this study
aICD-O: International Classification of Diseases for Oncology 1976-
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age at diagnosis between 70 and 80, diagnosed between
1981 and 2010 and born between 1910 and 1930, which
means that the model includes reliable information from
the birth cohorts of interest.
5-year relative survival, based on the cohort ap-
proach, was estimated using the age-standardardized
Ederer II method applying national population life-
tables by sex, age group and diagnosis period [25]. The
internal age-standardization used the age distribution
of the last diagnostic period 2011-14 as weights.
Temporal trends of 5-year relative survival rates were
best represented by a linear model. Thus, the average
absolute change in annual 5-year relative survival esti-
mates was provided together with the standard error
and p-values for the test of a significant trend. We also
implemented a joinpoint analysis [21] to uncover those
trends, which change over time. The annual change in
5-year survival proportions was estimated by the re-
gression coefficient β^RS: Because follow-up data for the
latest diagnostic period are lacking, 5-year survival esti-
mates for 2011-14 are based on a period approach. The
corresponding column is marked with an (*) in order to
emphasize the differently derived estimates and these
estimates have not been included in the trend analysis.
We fitted a proportional excess hazard model [26–28]
where sex, diagnostic period, age group, morphology
group and stage were included as categorical variables.
The baseline hazard was modelled using 5df for the
spline variables using the Stata command stpm2 [29].
Excess mortality rates estimate the absolute difference
between the expected mortality rate (from lifetables) and
the observed mortality rate (from the data). The ratio of
these quantities, the excess mortality rate ratios (EMRR),
are in their interpretation similar to the hazard rate ratio
and thus represent the factor of which patients under a
certain condition are more likely to die compared to pa-
tients under another condition. EMRRs are reported to-
gether with 95 % confidence intervals (CI).




A total number of 33,761 cases was diagnosed with UCB
(transitional cell type) between 1981 and 2014. An over-
view over these patients with respect to sex as well as
vital status (UCB and other cancer related death, alive,
unknown), morphology group, stage, and age by sex and
combined is provided in Table 2. Three quarters of the
UCB patients diagnosed between 1981 and 2014 were
men. For all patients (men and women combined), the
median age at diagnosis was 72 years (inter-quartile
range: 64–79 years). The majority of patients (50.5 %)
were diagnosed with non-invasive papillary carcinoma
Ta (43.4 % low-grade, 7.1 % high-grade). Invasive transi-
tional carcinoma (T1-T4) accounted for 42.0 % of all
UCB cases in this study and carcinoma in situ (3.6 %) as
well as dysplasia (3.9 %) are the least frequent morph-
ology groups. Out of all patients diagnosed between
1981 and 2014, 66.6 % had died by 31st of March 2016,
either due to UCB (15.5 %), cancer (not UCB) (22.0 %)
or causes other than cancer (29.1 %). Women had rela-
tively more invasive (44.3 vs 41.3 %) and more advanced
(10.0 vs 8.5 %) tumors than men.
Incidence
Age-standardized incidence rates (World) are summa-
rized in seven diagnostic periods in Table 3. In
addition, estimates for the average annual incidence
change β^I
 
are provided. These quantities estimate the
average incidence trend throughout the study period and
give an indicator for whether (and how much) incidence
changed linearly over the past 34 years. For men, after a
slightly increasing trend in the 1980s, UCB incidence
has been stable throughout the remaining study period.
A joinpoint analysis revealed an increasing trend of
0.34 (p = 0.048) from 1981-89 and a stable trend from
1990 to 2014 ( β^I =0.02, p = 0.531). Thus, on average,
Table 2 Patient characteristics
Men Women All
% 75.6 24.4 100.0
Age [25–75 % percentile] 72 [64–79] 73 [65–81] 72 [64–79]
Morphology
Non-inv pap trans carcinoma
low-grade
43.4 43.0 43.4
Non-inv pap trans carcinoma
high-grade
7.6 5.6 7.1
Displasia 3.9 4.1 3.9
Carcinoma in situ 3.7 3.1 3.6
Inv trans carcinoma 41.3 44.3 42.0
Stage
Localised 91.5 89.9 91.1
Regional advanced 5.6 5.9 5.7
Distant advanced 2.9 4.1 3.2
Death
Bladder cancer 15.0 17.2 15.5
Other cancer 22.1 21.4 22.0
Other than cancer 30.2 26.2 29.1
Unknown 2.7 2.6 2.8
Alive 30.0 32.6 30.6
Distribution of age, morphology group, stage and cause of death by sex and
in total in the study population of patients diagnosed with urothelial
carcinoma of the urinary bladder in Norway from 1981 to 2014
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the incidence increased by 0.34 β^I
 
within a year or
2.7 from 1981 to 1989. The remaining 26 years of the
study period, the incidence increased on average 0.02
per year or 0.5 from 1990 to 2014. The incidence of
UCB in men was between 18.3 and 21.4 per 100 000
person-years for all diagnostic periods during the study
period. The incidence of UCB was lower in women
with incidence rates increasing from 4.7 to 6.2 over the
past 34 years. The corresponding trend was significant:
β^I = 0.043 (p = 5.9 · 10
-7).
In men, age-specific incidence rates were increasing
during the past 34 years, especially for the oldest patients
(β^I = 3.5, p = 7.1 · 10
-9) and those between 65 and 79 (β^I =
0.9, p = 3.2 · 10-5). Similar age-dependent incidence trends
could also be seen in women, although less pronounced
probably due to the lower number of cases. This observed
Table 3 Incidence rates
1981-1985 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2014 βI (SE) p-value
Men n 2972 3321 3628 3575 3928 4192 3915
18.5 19.7 21.1 19.7 20.6 20.4 21.4 0.070(0.021) 0.002a
Women n 974 1038 1110 1150 1262 1380 1316
4.7 4.9 5.2 5.1 5.3 5.7 6.2 0.043(0.007) 5.9E-07a
Men Age (years)
0–49 2.0 1.8 2.1 2.0 1.9 1.8 2.5 0.008(0.007) 0.246
50–64 46.2 49.0 50.4 40.3 42.4 42.6 44.4 −0.196(0.102) 0.065
65–79 148.4 156.0 171.0 169.1 175.4 176.1 173.1 0.899(0.186) 3.2E-05a
80+ 194.1 256.2 263.1 268.0 301.8 286.1 317.8 3.47(0.45) 7.1E-09a
Morphology
Non-inv pap carcinoma LG 8.7 9.5 9.9 9.2 9.5 8.9 8.3 −0.016(0.016) 0.335
Non-inv pap carcinoma HG 0.6 0.9 1.3 0.9 1.4 2.3 2.6 0.061(0.006) 1.5E-10a
Dysplasia 0.6 0.7 1.0 0.9 0.6 0.6 1.4 0.011(0.006) 0.070
Carcinoma in situ 0.4 0.7 0.7 0.9 0.9 0.9 0.7 0.013(0.003) 0.002a
Inv carcinoma 8.2 8.0 8.2 7.8 8.2 7.7 8.4 −0.001(0.010) 0.985
Stage
Localised 16.6 17.9 19.6 18.2 18.6 18.5 19.9 0.072(0.021) 0.001a
Regional advanced 1.3 1.1 1.0 0.8 1.3 1.4 1.0 0.001(0.005) 0.919
Distant advanced 0.6 0.7 0.5 0.7 0.7 0.6 0.4 −0.003(0.003) 0.380
Women Age (years)
0–49 0.7 0.7 0.8 0.7 0.6 0.7 0.8 0.001(0.004) 0.739
50–64 12.3 13.0 12.8 11.6 13.8 14.1 15.0 0.083(0.034) 0.021a
65–79 34.2 35.7 39.2 41.3 41.2 44.8 47.5 0.425(0.061) 6.4E-08a
80+ 57.0 52.9 50.8 52.3 61.2 61.4 76.3 0.519(0.167) 0.004a
Morphology
Non-inv pap carcinoma LG 2.1 2.4 2.4 2.5 2.8 2.8 2.6 0.022(0.005) 1.0E-04a
Non-inv pap carcinoma HG 0.1 0.1 0.3 0.2 0.2 0.4 0.6 0.014(0.002) 5.4E-08a
Dysplasia 0.2 0.2 0.2 0.2 0.2 0.2 0.6 0.006(0.003) 0.037a
Carcinoma in situ 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.002(0.001) 0.233
Inv carcinoma 2.3 2.0 2.2 1.9 2.0 2.1 2.3 −0.001(0.005) 0.823
Stage
Localised 4.2 4.4 4.7 4.5 4.7 5.0 5.7 0.040(0.008) 8.6E-06a
Regional advanced 0.4 0.3 0.2 0.3 0.4 0.4 0.3 0.001(0.001) 0.611
Distant advanced 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.002(0.001) 0.172
Age-standardized incidence rates (applying the World Standard Population) by sex, morphology group and stage as well as age-specific incidence rates stratified
for 5-years interval of diagnosis from 1981 to 2014. Average annual incidence changes β^ I
 
are reported together with standard error (SE) and the p-value for the
test of a significant incidence trend. Significant p-values (based on the 5 % threshold) are marked witha
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pattern was most likely mainly due to a birth cohort effect
as illustrated in Fig. 1. The APC model confirmed the age-
effect (Fig. 1a) and suggested a larger birth cohort effect
compared to the diagnosis period effect (Fig. 1b). The inci-
dence rate ratio (IRR) was 1.22 (CI: 1.04–1.45) when com-
paring the 1930 birth cohort to the one from 1910. This
particular birth cohort effect stayed the same when redu-
cing the model to an age-cohort model (results not
shown).
In men, there was a significant increase in high-grade
non-invasive papillary carcinoma (Ta HG: p = 1.5 · 10-10)
over the study period. Age-standardized incidence rates
in men have been rather stable over the whole observa-
tion period for invasive carcinoma (p = 0.985) and low-
grade non-invasive papillary carcinoma (Ta LG p =
0.335). The incidence of both high- and low-grade non-
invasive papillary carcinoma (Ta) was increasing in
women (HG p = 5.4 · 10-8, LG p = 1.0 · 10-4). The corre-
sponding increase of incidence rates for carcinoma in
situ has been less pronounced in women (p = 0.233),
possibly due to small numbers of cases. A joinpoint
analysis reveals that the increase in incidence rates of
high-grade non-invasive papillary carcinoma is rather
small until 2001 (men: p = 0.055) and 2003 (women: p
= 0.105), but significant thereafter (men: p = 1.0 · 10-8,
women: men: p = 1.0 · 10-8).
Both genders showed an increasing trend with respect
to the incidence rates for localized cancers. This trend
was more pronounced for women (p = 8.6 · 10-6) than
men (p = 0.001). Cases with advanced stage were rather
rare, such that the interpretation suffered from small
number of cases in both men and women. Still, there is
a decreasing tendency for distant advanced tumors in
men (p = 0.380), while the corresponding tendency in
women is increasing (p = 0.172).
Relative Survival
Table 4 presents the sex-specific 5-year relative survival
across 5-year diagnosis intervals from 1981 to 2014
stratified for age and morphology group as well as stage.
Furthermore, the average annual survival change β^RS
 
estimates the average trend of the 5-year relative survival
Fig. 1 Age-standardized incidence rates per 100 000 person-years (a) and incidence rate ratios for birth cohort and diagnostic period effects for
men diagnosed with urothelial carcinoma of the urinary bladder in Norway (b)
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Table 4 Relative survival proportions
1981-85 1986-90 1991-95 1996-2000 2001-05 2006-10 2011-14a βRS (SE) p-value
Men 0.67 (0.64,0.70) 0.71 (0.68,0.74) 0.73 (0.70,0.76) 0.72 (0.70,0.75) 0.75 (0.72,0.77) 0.77 (0.75,0.79) 0.77 (0.75,0.79) 0.004 (0.001) 1.3E-06b
Women 0.63 (0.59,0.67) 0.68 (0.64,0.72) 0.65 (0.61,0.69) 0.70 (0.67,0.74) 0.70 (0.67,0.73) 0.72 (0.69,0.75) 0.74 (0.71,0.77) 0.003 (0.001) 4.5E-06b
Men Age (years)
0–49 0.90 (0.84,0.95) 0.85 (0.78,0.90) 0.93 (0.88,0.97) 0.92 (0.86,0.95) 0.89 (0.83,0.93) 0.91 (0.85,0.95) 0.94 (0.84,0.98) 0.001 (0.001) 0.623
50–64 0.78 (0.74,0.81) 0.81 (0.78,0.85) 0.83 (0.80,0.86) 0.84 (0.80,0.87) 0.84 (0.81,0.86) 0.83 (0.81,0.86) 0.89 (0.85,0.91) 0.003 (0.001) 0.006b
65–79 0.69 (0.65,0.72) 0.68 (0.65,0.72) 0.72 (0.70,0.75) 0.73 (0.70,0.76) 0.75 (0.72,0.78) 0.78 (0.76,0.81) 0.78 (0.73,0.81) 0.005 (0.001) 7.6E-07b
80+ 0.53 (0.45,0.63) 0.65 (0.57,0.73) 0.63 (0.56,0.71) 0.60 (0.53,0.66) 0.64 (0.58,0.70) 0.68 (0.62,0.73) 0.63 (0.54,0.72) 0.007 (0.003) 0.015b
Morphology
Non-inv pap carcinoma LG 0.85 (0.79,0.89) 0.92 (0.87,0.95) 0.91 (0.87,0.95) 0.93 (0.88,0.96) 0.91 (0.87,0.94) 0.94 (0.90,0.97) 0.93 (0.84,0.97) 0.003 (0.001) 0.001b
Non-inv pap carcinoma HG 0.94 (0.18,1.00) 0.76 (0.63,0.85) 0.84 (0.71,0.92) 0.80 (0.66,0.88) 0.82 (0.72,0.88) 0.87 (0.80,0.92) 0.88 (0.77,0.94) 0.004 (0.002) 0.050
Dysplasia 0.76 (0.56,0.87) 0.63 (0.47,0.76) 0.76 (0.61,0.86) 0.83 (0.68,0.92) 0.85 (0.67,0.93) 0.83 (0.66,0.92) 0.74 (0.54,0.86) 0.004 (0.003) 0.155
Carcinoma in situ 0.79 (0.45,0.93) 0.62 (0.48,0.74) 0.64 (0.51,0.75) 0.64 (0.53,0.73) 0.84 (0.69,0.92) 0.83 (0.71,0.90) 0.91 (0.70,0.97) 0.013 (0.004) 1.6E-04b
Inv carcinoma 0.47 (0.43,0.51) 0.49 (0.45,0.52) 0.51 (0.48,0.55) 0.50 (0.47,0.54) 0.54 (0.50,0.57) 0.55 (0.52,0.58) 0.58 (0.54,0.63) 0.003 (0.001) 2.3E-04b
Stage
Localised 0.73 (0.69,0.76) 0.76 (0.73,0.79) 0.77 (0.74,0.79) 0.77 (0.74,0.79) 0.80 (0.78,0.82) 0.82 (0.80,0.84) 0.81 (0.77,0.84) 0.004 (0.001) 7.0E-06b
Regional advanced 0.25 (0.17,0.34) 0.27 (0.20,0.36) 0.28 (0.19,0.38) 0.23 (0.15,0.31) 0.25 (0.18,0.32) 0.27 (0.21,0.33) 0.22 (0.04,0.49) <0.001 (0.002) 0.991
Distant advanced 0.05 (0.02,0.11) 0.08 (0.04,0.14) 0.05 (0.01,0.15) 0.04 (0.01,0.12) 0.09 (0.04,0.17) 0.07 (0.03,0.12) 0.05 (0.01,0.030) −0.001 (0.002) 0.509
Women Age (years)
0–49 0.90 (0.76,0.96) 0.82 (0.68,0.90) 0.87 (0.75,0.94) 0.95 (0.84,0.99) 0.82 (0.67,0.91) 0.79 (0.65,0.88) 0.78 (0.61,0.89) −0.003 (0.003) 0.409
50–64 0.78 (0.71,0.84) 0.85 (0.78,0.90) 0.79 (0.72,0.84) 0.84 (0.78,0.89) 0.82 (0.76,0.86) 0.89 (0.84,0.92) 0.86 (0.77,0.92) 0.004 (0.002) 0.032b
65–79 0.61 (0.56,0.66) 0.64 (0.59,0.69) 0.65 (0.60,0.69) 0.72 (0.67,0.76) 0.74 (0.69,0.79) 0.72 (0.67,0.76) 0.70 (0.63,0.77) 0.008 (0.001) 1.5E-05b
80+ 0.51 (0.40,0.62) 0.59 (0.48,0.70) 0.52 (0.42,0.61) 0.53 (0.44,0.62) 0.51 (0.44,0.59) 0.59 (0.51,0.66) 0.68 (0.56,0.79) 0.004 (0.003) 0.195
Morphology
Non-inv pap carcinoma LG 0.92 (0.82,0.96) 0.94 (0.83,0.98) 0.90 (0.82,0.94) 0.92 (0.85,0.96) 0.90 (0.84,0.94) 0.91 (0.85,0.95) 0.89 (0.78,0.95) −0.001 (0.001) 0.585
Non-inv pap carcinoma HG 0.74 (0.36,0.92) 0.90 (0.34,0.99) 0.71 (0.51,0.83) 0.88 (0.27,0.99) 0.79 (0.60,0.90) 0.81 (0.68,0.89) 0.88 ((0.69,0.95) <0.001 (0.005) 0.986
Dysplasia 0.52 (0.35,0.66) 0.65 (0.46,0.79) 0.84 (0.46,0.96) 0.78 (0.54,0.91) 0.96 (0.11,1.00) 0.78 (0.57,0.90) 0.93 (0.46,0.99) 0.011 (0.005) 0.035b
Carcinoma in situ 0.39 (0.15,0.62) 0.60 (0.41,0.75) 0.73 (0.52,0.86) 0.81 (0.57,0.93) 0.62 (0.50,0.72) 0.71 (0.51,0.84) 0.83 (0.29,0.97) 0.010 (0.006) 0.082
Inv carcinoma 0.43 (0.38,0.48) 0.43 (0.37,0.48) 0.42 (0.37,0.47) 0.46 (0.41,0.51) 0.45 (0.40,0.50) 0.51 (0.46,0.56) 0.50 (0.43,0.57) 0.003 (0.001) 0.010b
Stage
Localised 0.70 (0.66,0.74) 0.74 (0.69,0.78) 0.70 (0.66,0.73) 0.76 (0.72,0.79) 0.77 (0.74,0.80) 0.79 (0.76,0.82) 0.79 (0.74,0.83) 0.004 (0.001) 9.2E-06b
Regional advanced 0.14 (0.06,0.24) 0.19 (0.10,0.29) 0.18 (0.10,0.28) 0.30 (0.20,0.40) 0.18 (0.11,0.26) 0.25 (0.16,0.35) 0.30 (0.18,0.43) 0.004 (0.02) 0.055
Distant advanced 0.04 (0.01,0.15) 0.09 (0.01,0.27) 0.02 (0.01,0.10) 0.04 (0.01,0.10) 0.06 (0.01,0.16) 0.11 (0.05,0.22) 0.08 (0.01,0.41) −0.010 (0.006) 0.136
5-year relative survival proportions (Ederer II) including confidence intervals by sex, morphology group and stage stratified by 5-year diagnosis intervals from 1981 to 2014. We applied internal age-standardization
based on the latest diagnostic period 2011-14. Average annual relative survival proportion changes β^RS
 
are reported together with standard error (SE) and p-value for the test of a significant survival trend.
aThe relative survival values for the latest diagnostic period are based on a period approach












proportions throughout the study period. It gives an in-
dicator for whether (and how much) survival changed
over the past 30 years. On average, 5-year relative survival
proportions increased annually by β^RS =0.004 in men (p =
1.3 · 10-6) and β^RS =0.003 in women (p = 4.5 · 10
-6). In men,
the 5-year relative survival was 0.67 (CI: 0.64–0.70) in
1981-85 and 0.77 (CI: 0.75–0.79) in 2006-10. The corre-
sponding 5-year relative survival in women were 0.63 (CI:
0.59–0.67) for 1981-85 and 0.72 (CI: 0.69–0.75) in 2006-10.
The age-specific 5-year relative survival in men stayed
mainly stable within the youngest age group (≤50 years),
while improvement in relative survival was the more pro-
nounced the older the patient was (≥80 years: β^RS =0.007,
p = 0.015). In women, these trends were similar except that
the increase in 5-year relative survival was most distinct in
the age group 65–79 years (β^RS =0.008, p = 1.5 · 10
-5). There
was a significant increase in 5-year relative survival for inva-
sive carcinomas in both men (β^RS =0.003, p = 2.3 · 10
-4) and
women (β^RS =0.003, p = 0.010). Relative survival for local-
ized stages were significantly larger towards the end of the
study period in both men ( β^RS =0.004, p = 7.0 · 10
-6) and
women ( β^RS =0.004, p = 9.2 · 10
-6). There is no significant
increase in survival for advanced stages, the tendency is
towards decreasing survival for the distant advanced stage
in both genders. Joinpoint analysis did not reveal any
significant changes in the trend over time.
We estimated the influence from the variables considered
in our study (sex, age, diagnosis period, morphology group,
stage) on the relative survival estimates and the results are
illustrated in Fig. 2. The largest impact on relative survival
had a diagnosis where the patient had metastases and/or
any infiltration into surrounding areas. Patients with distant
advanced tumors are 8.5 times more likely to die than pa-
tients with localized tumors (excess mortality rate ratio
EMRR= 8.5, CI: 7.8–9.2). The corresponding EMRR for re-
gional advanced tumors is 3.2 (CI: 3.0–3.4) when compared
to localized tumors. The most severe diagnosis of having an
invasive tumor lead to an EMRR of 6.1 (CI: 5.4–6.8) when
comparing to the least severe diagnosis of a low-grade non-
invasive papillary carcinoma. Carcinoma in situ (EMRR 3.2,
CI: 2.7–3.9), dysplasia (EMRR 2.4, CI: 1.9–2.9) and high-
grade papillary carcinoma (EMRR 2.3, CI: 1.9–2.7) also in-
creased the EMRR significantly. The EMRR increased ex-
ponentially with age with an EMRR of 4.0 (CI: 3.3–4.8) for
patients 80 years old (and older). The excess mortality rate
was 1.2 times higher in women compared to men (CI: 1.1–
1.3). All these effects were strongly significant.
Discussion
This paper presents trends in incidence and survival for
patients diagnosed with urothelial carcinoma of the urin-
ary bladder in Norway between 1981 and 2014.
Incidence of UCB in men and women has significantly
increased throughout the study period. While this trend
was rather linear for women, for men an initial increase
of incidence rates in the eighties was observed, followed
by stable incidence rates. Interestingly, a similar pattern
has been observed in lung cancer, which is also a
smoking-related cancer type. A recent report [31]
showed that the lung cancer incidence rates in men lev-
elled off while incidence rates in females were still
Fig. 2 Estimated excess mortality rate ratios (EMRRs) and confidence intervals for sex, age group, diagnostic period, morphology and stage based
on a proportional excess hazard model
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increasing in Norway. A possible explanation is that the
trends for lung cancer and UCB both reflect the vari-
ation in smoking habits in the Norwegian population.
While the percentage of daily male smokers between 16
and 74 years has been almost linearly decreasing from
1973 (52 %) to 2014 (13 %) in Norway, the correspond-
ing percentage for female smokers kept stable from 1973
through 1999 (31–34 %) and followed the smoking trend
in men thereafter [32]. In addition, the application of an
age-period-cohort model indicated that birth cohort ef-
fects, which are tightly connected to smoking patterns in
the population, could at least partly, explain the ob-
served trends. Furthermore, the overall increase in the
incidence of UCB can be explained by a significant in-
crease in the incidence of non-invasive tumours. In
comparison to our results, Abdollah et al [16] observed
a linear increasing trend in age-standardized incidence
of UCB from 21.0 to 25.5 per 100 000 person-years
within the last three decades in US men. The same au-
thors also reported an increased incidence for localized
stages, which is in line with our observations. In South
Australia, incidence increased during 1980 to 2004 for
carcinoma in situ and invasive UCB combined [15] while
invasive UCB stayed stable in Norway. However, we also
observed an increase in high-grade non-invasive carcin-
oma (Tis, Ta) over time in men. Our data on sex differ-
ences in incidence are in line with other contemporary
publications [33–35].
We have shown a small overall improvement in 5-
year relative survival proportions over the past three
decades. This improvement can particularly be seen in
older patients and in those suffering from carcinoma
in situ. There is no significant survival improvement
for advanced tumors in either sex. This could be inter-
preted as a sign of a negligible effect of the increased
use of cystectomy during the study period. Since this
treatment was also increasingly used for elderly pa-
tients, the same explanation could also apply to the
small but apparent survival improvement in elderly
patients. However, the largest improvement was seen
for flat non-invasive tumors in women and non-
invasive tumors in men, which might reflect the intro-
duction of immunotherapy (Bacillus Calmette-Guerin)
in the 1990s in Norway. In South Australia, there was
a decrease in 5-year survival proportions from 64 to
58 % observed during 1980 to 2004 for in situ and in-
vasive UCB combined [15]. Survival trends in
Switzerland for malignant UCB (non-invasive papillary
and in situ carcinomas excluded) concluded with little
survival improvement based on data from 1991 to
2010 [17]. A study investigating the variation of tem-
poral trends with respect to sociodemographic and so-
cioeconomic factors illustrated the underlying
disparities associated with detection and treatment of
UCB and indicated the “necessity of debate of devel-
oping a valid screening procedure for UCB” at least
for particular risk groups [16].
Modelling excess mortality with respect to the vari-
ables included in our study confirmed advanced tu-
mors, invasive tumors, flat tumors and high-grade
tumors as well as older age as risk factors. Sex and
diagnosis period also play a significant role, but to a
lesser extent. Sex differences in survival have been
widely discussed. Differences with respect to the under-
lying anatomy, delays in diagnosis in females, as well as
variations in hormone receptors and tumor biology
might play a key role [36–38].
Relative survival estimates rely on population life ta-
bles rather than using cause-specific death information.
Pros and cons have been widely discussed with a general
agreement on the use of relative survival to estimate net
survival for population-based studies. The main concern
about using relative survival is the estimation of the
underlying expected survival in the population. The latter
needs to be a comparable group from the general popula-
tion, comparable also with respect to certain confounders
like smoking. The use of a general population lifetable,
and not a lifetable adjusted for smoking, may have led to
an underestimate of relative survival [39–41]. In a recent
comparison of methods for estimating net survival, the
Ederer II method [25] seemed to be the best choice [42].
The main limitation of this study is that we were not
able to distinguish between muscle-invasive (T2-4) and
non-muscle invasive (T1) cancers because these tumors
are condensed to the same morphology group in our
cancer registry. However, we did have information about
the existence of metastases with tumors classified into
three stages: localized (non-invasive/invasive cancer
without any metastasis), regional advanced (any infiltra-
tion into surrounding areas or regional metastases) and
distant advanced (distant metastases) tumors. The local-
ized group contains tumors without metastases but also
included those with unrecognized metastases. The rea-
son for that is a coding change in 1993 with respect to
the latter group, which does not allow us to separate no-
metastasis patients from those with unknown spread.
Another drawback is that we had to use grading infor-
mation based on the WHO 1973 system, such that our
definition of low- and high grade is partly different from
the WHO/ISUP 2004 system since we define low-grade
tumors to include WHO grade 1 and 2 and high-grade
tumors WHO grade 3.
Conclusion
This study gives a comprehensive overview over inci-
dence and survival changes related to a diagnosis of
urothelial carcinoma of the urinary bladder in Norway
from 1981 to 2014. To our knowledge, this is the only
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nationwide investigation of incidence and survival
worldwide. The main conclusion is, that survival propor-
tions increased only marginally. Thus, any changes in
treatment and follow-up care did not lead to notable im-
provement with respect to survival of the patients. This
conclusion gets support from several other studies look-
ing at these trends over time [15–17]. High estimates of
preventive cases together with high recurrence and pro-
gression rates of this particular cancer type, demands
more research on prevention guidelines, diagnostic tools
and treatment for bladder cancer.
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